Doer Bio, a clinical stage biopharmaceutical company, has partnered with BioNTech SE to develop innovative biotherapeutics for metabolic diseases and cancers. This exciting new agreement will allow Doer Bio to leverage BioNTech’s groundbreaking technology to create potential treatments that can change people’s lives for the better.
Doer Bio and BioNTech have joined forces to bring revolutionary biotherapeutics to the world. Under the terms of the agreement, Doer Bio has granted BioNTech a worldwide license to utilize one of their groundbreaking discoveries in order to research, develop, manufacture, and commercialize unique medicine against a specific target.
In exchange, Doer Bio will not only receive an upfront payment but also have the opportunity to gain additional funds through the completion of various development, regulatory, and commercial milestones.
Doer Bio’s platform technologies have been extensively pre-clinically validated and are currently subject to ongoing clinical studies – showcasing their immense potential. This was further emphasised through a revolutionary license agreement the company recently signed with BioNTech. Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio, comments: “This agreement is a great testament to the potential of our platform technologies.”
We are incredibly excited to join forces with BioNTech, a world-renowned biopharmaceutical powerhouse, to turn our developments into dynamic, life-saving therapies. Together, we are committed to drive forward this cutting-edge technology and make it accessible to people everywhere, ultimately paving a way to a healthier future.
About Doer Bio
Doer Bio is a pioneering biopharmaceutical company at the cutting edge of medical innovation, committed to developing multiple-domain biotherapeutics that could help millions around the world overcome metabolic diseases and cancer. With its groundbreaking therapeutics, Doer Bio is bringing hope for those in need of better treatments and better lives.
Doer Bio has created a range of cutting-edge technologies, such as xLONGylation®, MultipleBody®, AccuBody® and SMART-VHHBody that promise to revolutionize the way we think about biodiscovery. These proprietary platforms have the potential to allow for fast, accurate, and economical access to the discovery and development of biosimilars and biobetters.